How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
63
AZN Quote, Financials, Valuation and Earnings
Last price:
$187.34
Seasonality move
:
3.98%
Day range:
$186.58 - $190.67
52-week range:
$122.48 - $193.02
Dividend yield:
1.67%
P/E ratio:
62.15x
P/S ratio:
10.06x
P/B ratio:
12.65x
Volume:
3.4M
Avg. volume:
3.8M
1-year change:
31.92%
Market cap:
$580.3B
Revenue:
$54.1B
EPS (TTM):
$3.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$15.4B | $1.08 | 6.96% | 31.42% | $105.00 |
|
AMGN
Amgen, Inc.
|
$9.5B | $4.73 | 7.24% | 54.39% | $340.00 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
GSK
GSK Plc
|
$6.1B | $0.62 | -40.54% | 17.99% | $52.85 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $3.45 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.75 | 13.93% | 25.81% | $859.58 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$187.16 | $105.00 | $580.3B | 62.15x | $1.03 | 1.67% | 10.06x |
|
AMGN
Amgen, Inc.
|
$367.80 | $340.00 | $198.2B | 25.85x | $2.38 | 2.59% | 5.43x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.30 | $17.94 | $1.1M | -- | $0.00 | 0% | 0.73x |
|
GSK
GSK Plc
|
$59.16 | $52.85 | $118.9B | 18.20x | $0.43 | 2.86% | 2.90x |
|
MREO
Mereo BioPharma Group Plc
|
$0.41 | $3.45 | $65.2M | -- | $0.00 | 0% | 128.02x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$775.06 | $859.58 | $81.5B | 18.65x | $0.88 | 0.45% | 5.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.56% | -0.049 | 13.71% | 0.66x |
|
AMGN
Amgen, Inc.
|
86.31% | -0.321 | 30.95% | 0.73x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
GSK
GSK Plc
|
52.36% | -0.226 | 27.67% | 0.53x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.707 | 0.12% | 8.09x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
7.97% | -0.011 | 3.34% | 4.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
AMGN
Amgen, Inc.
|
$8.1B | $3.9B | 11.99% | 102.03% | 39.83% | $1.6B |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
GSK
GSK Plc
|
-- | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.3B | $898.6M | 13.68% | 14.93% | 23.13% | $1.4B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 13.51%. AstraZeneca PLC's return on equity of 22.01% beat Amgen, Inc.'s return on equity of 102.03%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B AMGNAmgen, Inc.81.86% $2.45 $63.3B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $105.00, signalling downside risk potential of -43.9%. On the other hand Amgen, Inc. has an analysts' consensus of $340.00 which suggests that it could fall by -7.56%. Given that AstraZeneca PLC has more downside risk than Amgen, Inc., analysts believe Amgen, Inc. is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 AMGNAmgen, Inc.10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.492%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.03 per share corresponding to a yield of 1.67%. Amgen, Inc. offers a yield of 2.59% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Amgen, Inc. pays out 66.9% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Amgen, Inc. quarterly revenues of $9.9B. AstraZeneca PLC's net income of $2.5B is higher than Amgen, Inc.'s net income of $1.3B. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.15x while Amgen, Inc.'s PE ratio is 25.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.06x versus 5.43x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.06x 62.15x $15.1B $2.5B AMGNAmgen, Inc.5.43x 25.85x $9.9B $1.3B
-
Which has Higher Returns AZN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 22.01% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AZN or BDRX?
AstraZeneca PLC has a consensus price target of $105.00, signalling downside risk potential of -43.9%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 13580.87%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than AstraZeneca PLC, analysts believe Biodexa Pharmaceuticals Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AZN or BDRX More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock AZN or BDRX?
AstraZeneca PLC has a quarterly dividend of $1.03 per share corresponding to a yield of 1.67%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BDRX?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.5B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.15x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.06x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.06x 62.15x $15.1B $2.5B BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AZN or GSK?
GSK Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 25.09%. AstraZeneca PLC's return on equity of 22.01% beat GSK Plc's return on equity of 42.84%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GSKGSK Plc73.8% -- $45.1B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $105.00, signalling downside risk potential of -43.9%. On the other hand GSK Plc has an analysts' consensus of $52.85 which suggests that it could fall by -8.53%. Given that AstraZeneca PLC has more downside risk than GSK Plc, analysts believe GSK Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 GSKGSK Plc1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.34%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.03 per share corresponding to a yield of 1.67%. GSK Plc offers a yield of 2.86% to investors and pays a quarterly dividend of $0.43 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.5B is lower than GSK Plc's net income of $2.9B. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.15x while GSK Plc's PE ratio is 18.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.06x versus 2.90x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.06x 62.15x $15.1B $2.5B GSKGSK Plc2.90x 18.20x $11.5B $2.9B
-
Which has Higher Returns AZN or MREO?
Mereo BioPharma Group Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of -2923.31%. AstraZeneca PLC's return on equity of 22.01% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About AZN or MREO?
AstraZeneca PLC has a consensus price target of $105.00, signalling downside risk potential of -43.9%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.45 which suggests that it could grow by 544.35%. Given that Mereo BioPharma Group Plc has higher upside potential than AstraZeneca PLC, analysts believe Mereo BioPharma Group Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 MREOMereo BioPharma Group Plc4 2 0 -
Is AZN or MREO More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.310, suggesting its less volatile than the S&P 500 by 68.983%.
-
Which is a Better Dividend Stock AZN or MREO?
AstraZeneca PLC has a quarterly dividend of $1.03 per share corresponding to a yield of 1.67%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MREO?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.5B is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.15x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.06x versus 128.02x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.06x 62.15x $15.1B $2.5B MREOMereo BioPharma Group Plc128.02x -- -- -$7M
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 21.74%. AstraZeneca PLC's return on equity of 22.01% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B REGNRegeneron Pharmaceuticals, Inc.85.9% $7.86 $34B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $105.00, signalling downside risk potential of -43.9%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $859.58 which suggests that it could grow by 10.91%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than AstraZeneca PLC, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $1.03 per share corresponding to a yield of 1.67%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. AstraZeneca PLC's net income of $2.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.15x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.06x versus 5.87x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.06x 62.15x $15.1B $2.5B REGNRegeneron Pharmaceuticals, Inc.5.87x 18.65x $3.9B $844.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
59
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
58
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 0.91% over the past day.
Buy
73
ENPH alert for Feb 6
Enphase Energy, Inc. [ENPH] is down 8.53% over the past day.
Sell
25
MRCY alert for Feb 5
Mercury Systems, Inc. [MRCY] is up 2.61% over the past day.
